Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC

The rationale for the new sequence of pulsed dose chemotherapy proposed in this trial is based on the hypotheses that current standard dosing of chemotherapy plus pembrolizumab ultimately suppresses the immune system and has a negative effect on the efficacy of the anti-PD-1 monoclonal antibody (mAb) therapy and that chemotherapy given after anti-PD-1 mAb therapy is associated with higher efficacy.

Trial Details

NCT ID
NCT06052839
Phase
PHASE2
Sponsor
Dan Zandberg
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Pembrolizumab
  • Carboplatin
  • Paclitaxel
Locations (sample)
  • Pittsburgh, Pennsylvania, United States|40.44062,-79.99589

Key Eligibility Criteria

  • Recurrent/metastatic squamous cell carcinoma of the head and neck that is considered incurable by local therapies.
  • PD-L1 Combined Positive Score (CPS) \>1
  • Age \> 18 years.
  • Eastern Cooperative Oncology Group (ECOG) Performance Scale (PS) 0-2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →